William D. Figg
Impact in
- Oncology top 0.05%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
- Cancer Research top 0.2%
Papers in
- Oncology 238
- Cancer Treatment and Pharmacology 69
- Drug Transport and Resistance Mechanisms 44
- Cancer Immunotherapy and Biomarkers 31
-
- Protein Degradation and Inhibitors 39
- Cancer therapeutics and mechanisms 33
- Co-authors
- Alex Sparreboom (64 shared papers)Seth M. Steinberg (108 shared papers)Cindy H. Chau (46 shared papers)Charity D. Scripture (12 shared papers)William L. Dahut (92 shared papers)Cody J. Peer (126 shared papers)Tristan M. Sissung (64 shared papers)Douglas K. Price (58 shared papers)
- Journals
- Journal of Clinical Oncology (102 papers)Clinical Cancer Research (37 papers)Cancer Biology & Therapy (35 papers)Blood (17 papers)The Journal of Clinical Pharmacology (15 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
William D. Figg
594 papers receiving 25.1k citations
William D. Figg's Hit Papers
Peers
Comparison fields: 5 of 177
- Oncology 8.6k
- Cancer Research 2.9k
- Hematology 1.9k
- Molecular Biology 10.4k
- Pharmacology 1.1k
Countries citing papers authored by William D. Figg
This map shows the geographic impact of William D. Figg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William D. Figg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William D. Figg more than expected).
Fields of papers citing papers by William D. Figg
This network shows the impact of papers produced by William D. Figg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William D. Figg. The network helps show where William D. Figg may publish in the future.
Co-authors
The 25 scholars most cited alongside William D. Figg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 606 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Antibody–drug conjugates for cancer Hit paper breakdown → | 2019 | 597 |
| 2 | Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma Hit paper breakdown → | 2009 | 568 |
| 3 | 2004 | 463 | |
| 4 | 2005 | 403 | |
| 5 | 2010 | 403 | |
| 6 | 2000 | 375 | |
| 7 | 2011 | 362 | |
| 8 | 2004 | 350 | |
| 9 | 2005 | 347 | |
| 10 | 1998 | 337 | |
| 11 | Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. | 1996 | 320 |
| 12 | 2006 | 280 | |
| 13 | 2008 | 261 | |
| 14 | 2006 | 254 | |
| 15 | 2001 | 235 | |
| 16 | 2006 | 232 | |
| 17 | 2010 | 231 | |
| 18 | 2003 | 230 | |
| 19 | 2000 | 222 | |
| 20 | 2017 | 204 |
About William D. Figg
William D. Figg is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Hematology and Cancer Research, having authored 606 papers that have together received 25.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (116 papers), Cancer Treatment and Pharmacology (69 papers), Multiple Myeloma Research and Treatments (68 papers), Drug Transport and Resistance Mechanisms (44 papers), Protein Degradation and Inhibitors (39 papers), Cancer therapeutics and mechanisms (33 papers), Pharmacogenetics and Drug Metabolism (32 papers) and Cancer Immunotherapy and Biomarkers (31 papers). The work is most often cited by research in Oncology (8.6k citations), Cancer Research (2.9k citations), Hematology (1.9k citations), Molecular Biology (10.4k citations) and Pharmacology (1.1k citations). William D. Figg has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Alex Sparreboom, Seth M. Steinberg, Cindy H. Chau, Charity D. Scripture, William L. Dahut, Cody J. Peer, Tristan M. Sissung, Douglas K. Price, Erin R. Gardner and Kristina M. Cook. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Biology & Therapy, Blood and The Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.